OncoTargets and Therapy (Aug 2020)
NY-ESO-1 Protein Vaccine Combining Alum, CpG ODN, and HH2 Complex Adjuvant Induces Protective and Therapeutic Anti-Tumor Responses in Murine Multiple Myeloma
Abstract
Hao Wang,1 Wei Huang,2 Hua Gao,3 Ting Ting Liu4,5 1Department of Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu Medical College, Chengdu, Sichuan, People’s Republic of China; 2Department of Preventive Medicine, West China School of Public Health, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 3Department of Hematology, The Third People’s Hospital of Chengdu, Chengdu, Sichuan 610041, People’s Republic of China; 4Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, People’s Republic of China; 5Department of Hematology, West China Medical Center, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of ChinaCorrespondence: Ting Ting Liu Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pujian Road, Shanghai 200127, People’s Republic of ChinaTel +86-13882203124Email [email protected]: NY-ESO-1 is an ideal target for multiple myeloma immunotherapy. Alum, CpG ODN and HH2 complex is a safe and effective adjuvant for cancer vaccine.Methods: We constructed NY-ESO-1 protein vaccine combined with alum, CpG ODN, and HH2 complex adjuvant to immunize the BALB/c mice inoculated with NS-1 murine multiple myeloma cells. Then, we determined the immunogenicity and anti-tumor effects in prophylactic and therapeutic models by analyzing the NY-ESO-1 antibody titer, evaluating IL4/INF-γ expression, and assessing cytotoxic T lymphocytes activities. The side-effects of vaccines were also evaluated.Results: The group of NY-ESO-1 protein vaccine combining alum, CpG ODN, and HH2 complex adjuvant is more capable of stimulating both humoral and cellular tumor-specific immune responses to prolong the survival of the mice and inhibit tumor growth in prophylactic and therapeutic immunotherapy. The marked side-effects were not detected in immunized mice.Discussion: The results suggest that alum, CpG ODN, and HH2 complex as a novel immune adjuvant combined cancer vaccine could improve the immunity efficiency in a murine multiple myeloma model.Keywords: vaccine, alum, CpG ODN, HH2, complex adjuvant, immunity, multiple myeloma
